JP2020521794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521794A5 JP2020521794A5 JP2019566178A JP2019566178A JP2020521794A5 JP 2020521794 A5 JP2020521794 A5 JP 2020521794A5 JP 2019566178 A JP2019566178 A JP 2019566178A JP 2019566178 A JP2019566178 A JP 2019566178A JP 2020521794 A5 JP2020521794 A5 JP 2020521794A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- eldaphytinib
- fgfr2
- fgfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims description 18
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims description 18
- 108091008794 FGF receptors Proteins 0.000 claims description 13
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims description 13
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 8
- 206010004593 Bile duct cancer Diseases 0.000 claims description 6
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 7
- 239000010452 phosphate Substances 0.000 claims 7
- 210000002966 serum Anatomy 0.000 claims 7
- 230000002411 adverse Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023077882A JP2023113650A (ja) | 2017-06-02 | 2023-05-10 | 胆管癌の治療のためのｆｇｆｒ２阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17174295 | 2017-06-02 | ||
| EP17174295.0 | 2017-06-02 | ||
| EP18171315.7 | 2018-05-08 | ||
| EP18171315 | 2018-05-08 | ||
| PCT/EP2018/064523 WO2018220206A1 (en) | 2017-06-02 | 2018-06-01 | Fgfr2 inhibitors for the treatment of cholangiocarcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077882A Division JP2023113650A (ja) | 2017-06-02 | 2023-05-10 | 胆管癌の治療のためのｆｇｆｒ２阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020521794A JP2020521794A (ja) | 2020-07-27 |
| JP2020521794A5 true JP2020521794A5 (https=) | 2021-07-26 |
Family
ID=62555054
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566178A Withdrawn JP2020521794A (ja) | 2017-06-02 | 2018-06-01 | 胆管癌の治療のためのｆｇｆｒ２阻害剤 |
| JP2023077882A Pending JP2023113650A (ja) | 2017-06-02 | 2023-05-10 | 胆管癌の治療のためのｆｇｆｒ２阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077882A Pending JP2023113650A (ja) | 2017-06-02 | 2023-05-10 | 胆管癌の治療のためのｆｇｆｒ２阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11707463B2 (https=) |
| EP (1) | EP3634414A1 (https=) |
| JP (2) | JP2020521794A (https=) |
| KR (1) | KR20200010505A (https=) |
| CN (1) | CN111050769A (https=) |
| AU (1) | AU2018278271B2 (https=) |
| BR (1) | BR112019025056A2 (https=) |
| CA (1) | CA3064317A1 (https=) |
| IL (1) | IL271058A (https=) |
| JO (1) | JOP20190280A1 (https=) |
| MA (1) | MA49248A (https=) |
| MX (1) | MX2019014366A (https=) |
| MY (1) | MY204203A (https=) |
| PH (1) | PH12019502710A1 (https=) |
| UA (1) | UA126478C2 (https=) |
| WO (1) | WO2018220206A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6752715B2 (ja) | 2014-03-26 | 2020-09-09 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 組合せ |
| TWI719960B (zh) | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| PH12021551949A1 (en) * | 2019-02-12 | 2022-07-18 | Janssen Pharmaceutica Nv | Cancer treatment |
| AU2020253827B2 (en) * | 2019-03-29 | 2026-01-08 | Janssen Pharmaceutica Nv | FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| JP2022534742A (ja) * | 2019-05-28 | 2022-08-03 | キューイーディー セラピューティクス，インコーポレイテッド | 胆管癌を治療するための方法 |
| TW202114665A (zh) * | 2019-08-05 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種吡咯并六員雜環化合物在製備治療ｆｇｆｒ２基因變異的腫瘤的藥物中的用途 |
| CN114945367A (zh) * | 2020-01-17 | 2022-08-26 | 贝达医药公司 | 作为fgfr激酶抑制剂的哒嗪和1,2,4-三嗪衍生物 |
| CN111596058A (zh) * | 2020-05-18 | 2020-08-28 | 山东第一医科大学(山东省医学科学院) | 一种检测胆管癌患者外周血循环肿瘤细胞fgfr基因突变的试剂盒及检测方法 |
| DE102021126650A1 (de) | 2021-10-14 | 2023-04-20 | Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts | Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff |
| KR20250117064A (ko) | 2024-01-26 | 2025-08-04 | 충북대학교 산학협력단 | 아무렌신 g를 유효성분으로 포함하는 담관암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| MX2007014782A (es) | 2005-05-23 | 2008-02-19 | Novartis Ag | Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona. |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| KR20100015883A (ko) * | 2007-03-23 | 2010-02-12 | 더 트랜스내셔날 게노믹스 리서치 인스티튜트 | 자궁내막암 및 전암을 진단，분류 및 치료하는 방법 |
| GB201007286D0 (en) * | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| US9254288B2 (en) * | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| EP2945652B1 (en) * | 2013-01-18 | 2021-07-07 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| EP4063516A1 (en) | 2014-09-26 | 2022-09-28 | Janssen Pharmaceutica NV | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| AU2016341445B2 (en) | 2015-10-23 | 2020-08-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
| JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
-
2017
- 2017-06-16 JO JOP/2019/0280A patent/JOP20190280A1/ar unknown
-
2018
- 2018-06-01 AU AU2018278271A patent/AU2018278271B2/en not_active Ceased
- 2018-06-01 BR BR112019025056-5A patent/BR112019025056A2/pt not_active Application Discontinuation
- 2018-06-01 UA UAA201912271A patent/UA126478C2/uk unknown
- 2018-06-01 CN CN201880050198.0A patent/CN111050769A/zh active Pending
- 2018-06-01 MX MX2019014366A patent/MX2019014366A/es unknown
- 2018-06-01 WO PCT/EP2018/064523 patent/WO2018220206A1/en not_active Ceased
- 2018-06-01 MA MA049248A patent/MA49248A/fr unknown
- 2018-06-01 CA CA3064317A patent/CA3064317A1/en active Pending
- 2018-06-01 KR KR1020197038249A patent/KR20200010505A/ko not_active Ceased
- 2018-06-01 JP JP2019566178A patent/JP2020521794A/ja not_active Withdrawn
- 2018-06-01 MY MYPI2019007030A patent/MY204203A/en unknown
- 2018-06-01 EP EP18729631.4A patent/EP3634414A1/en active Pending
- 2018-06-01 US US16/616,067 patent/US11707463B2/en active Active
-
2019
- 2019-11-29 PH PH12019502710A patent/PH12019502710A1/en unknown
- 2019-12-01 IL IL271058A patent/IL271058A/en unknown
-
2023
- 2023-05-10 JP JP2023077882A patent/JP2023113650A/ja active Pending
- 2023-06-26 US US18/341,023 patent/US12350266B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020521794A5 (https=) | ||
| Cuisset et al. | Aspirin noncompliance is the major cause of “aspirin resistance” in patients undergoing coronary stenting | |
| Ness et al. | Frailty in childhood cancer survivors | |
| Perez‐Ruiz et al. | A two‐stage approach to the treatment of hyperuricemia in gout: the “dirty dish” hypothesis | |
| Morgan et al. | Mortality in Levodopa‐Treated Parkinson′ s Disease | |
| Gild et al. | Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells | |
| Frisch et al. | Superior water maze performance and increase in fear-related behavior in the endothelial nitric oxide synthase-deficient mouse together with monoamine changes in cerebellum and ventral striatum | |
| Shin et al. | Carotid body denervation prevents fasting hyperglycemia during chronic intermittent hypoxia | |
| Colle et al. | Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients | |
| Yin et al. | Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis | |
| JP2023113650A5 (https=) | ||
| Ji et al. | Irradiation-induced hippocampal neurogenesis impairment is associated with epigenetic regulation of bdnf gene transcription | |
| Wang et al. | BRG1 in the nucleus accumbens regulates cocaine-seeking behavior | |
| JP2020533381A5 (https=) | ||
| Moraska et al. | Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation study–NCCTG trial N00CB | |
| Sieland et al. | Changes in miRNA expression in patients with peripheral arterial vascular disease during moderate-and vigorous-intensity physical activity | |
| McCormick et al. | The effect of aging on the autophagic and heat shock response in human peripheral blood mononuclear cells | |
| Yan et al. | Clinical evaluation of the socket-shield technique for immediate implantation in the maxillary anterior region | |
| Mellwig et al. | Improved coronary vasodilatatory capacity by HELP apheresis: comparing initial and chronic treatment | |
| Suzuki et al. | Sustained-release lidocaine sheet for pain following tooth extraction: A randomized, single-blind, dose-response, controlled, clinical study of efficacy and safety | |
| Patrick et al. | The predictive value of fall assessment tools for patients admitted to hospice care | |
| Yeh et al. | EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid | |
| Lin et al. | Cancer-related fatigue | |
| CN104271763B (zh) | 对高强度电离放射线敏感的基因的检测方法及用所述方法检测的基因 | |
| Margolis | Antihypertensive medication use in older adults at risk for hip fracture |